XML 34 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
3 Months Ended
Mar. 31, 2025
Segment Reporting  
Segment Reporting

14. Segment Reporting

The Company operates as a single operating segment. Its operations consist of developing and commercializing innovative therapies for retinal diseases and other eye conditions based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology.

Resources are allocated and performance is assessed by the Company’s Chief Executive Officer and the Company’s Chief Financial Officer and Chief Operating Officer, who the Company has determined to be, collectively, the Company’s Chief Operating Decision Maker (“CODM”).

The accounting policies for the Company’s one segment are the same as those described in Note 2 Summary of Significant Accounting Policies. The CODM evaluates the performance of its one segment and allocates resources based on Net Loss.

The following table provides information about the Company’s single segment:

Three Months Ended March 31, 

2025

    

2024

Revenue

$

10,698

$

14,774

Cost of product revenue

1,262

1,326

Research and development (a)

Direct program expenses

AXPAXLI for wet AMD

24,455

5,493

Other clinical and preclinical programs

1,081

3,215

Unallocated expenses

Personnel costs

8,983

7,128

All other costs

3,255

802

Selling and marketing (a)

12,817

9,262

General and administrative (a)

9,661

8,344

Facilities (b)

1,664

1,923

Stock-based compensation

10,456

7,978

Depreciation

981

920

Interest income

3,826

3,922

Interest expense

(2,984)

(4,051)

Loss from debt extinguishment

(27,950)

Other non-operating items

(978)

(5,152)

Net loss

$

(64,053)

$

(64,848)

(a)excluding stock-based compensation, depreciation, and facilities expenses
(b)excluding stock-based compensation and depreciation